Uncategorized Archives - Page 47 of 87 - PsychedelicNewsWire (PNW)

ThursdayFeb 04, 2021 11:30 am

New Hawaii Senate Bill May See Psilocybin Mushroom Therapy Legalized

Hawaii may soon be the next state to legalize the use of psilocybin mushrooms if a bill, known as SB 738, that was recently filed in the state legislature is approved. According to SB 738, the state’s Department of Health would be directed to set up designated centers of treatment, where psilocin and psilocybin will be administered therapeutically. The two psychoactive compounds are produced by fungi from the genus Psilocybe. The measure’s approval would also lead to the creation of a seven-person panel for psilocybin review that would evaluate the influence of the change in policy, while also facilitating the…

WednesdayFeb 03, 2021 2:56 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Updates Investors Following Completion of Special Warrants Private Placement

Pure Extracts recently updated investors on successful completion of second tranche of its special warrants private placement In aggregate, Company will raise gross proceeds of $8.5 million through both tranches of private placement Pure Extracts will employ net proceeds from private placement towards capacity expansion for Company’s extraction business, and for general working capital purposes Company previously revealed that it was conducting study looking into formulation, manufacturing of psilocybin-based active treatments Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, has recently updated investors following the successful…

TuesdayFeb 02, 2021 3:35 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Is ‘One to Watch’

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities The company has research and development operations in North America and Europe and an operational focus in Germany XPhyto’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal and sublingual drug formulations, and psychedelic medicine The company’s lead diagnostic product is an accurate, rapid and highly portable PCR diagnostic test system being evaluated in Europe for the detection of COVID-19 XPhyto’s German subsidiary, Vektor Pharma TF GmbH, is advancing four therapeutic programs targeting neurological indications;…

TuesdayFeb 02, 2021 3:30 pm

Former Vancouver Firefighter Declares Psychedelic Drug Saved His Life

In the last few years, various scientific studies have shown how different psychedelic substances such as LSD, MDMA and magic mushrooms may help treat mental health conditions. This credible and extensive research has only propelled these drugs further into the mainstream. For many years now, these substances had been labeled as destructive and dangerous. However, science is now demonstrating how they hold great potential and could be used as alternative treatments for various ailments, such as PTSD, anxiety and depression, in the near future. It should be noted, however, that this only applies when they are administered in the correct medical…

MondayFeb 01, 2021 3:30 pm

Somerville, Massachusetts, Passes Measure to Decriminalize Psychedelics

Somerville has become the first community in Massachusetts to take a step toward decriminalizing entheogenic plants. The council conducted a vote to pass a resolution that advocated for the decriminalization of entheogenic plants, with the results being unanimous. The measure stated that Somerville employees, including police officers and officials from other agencies, should not utilize the city’s resources to help in enforcing laws against the possession and use of entheogenic plants by adults. However, the measure does not permit driving while under the influence of the said substances nor does it allow the commercial sale of the entheogens. One of…

FridayJan 29, 2021 1:15 pm

You Don’t Have to Take Psychedelics to Benefit from Them — Here’s How

Psychedelics have been in the spotlight for quite a while now and may be here to stay, given the immense therapeutic potential various psychedelic substances have demonstrated. For instance, psilocybin mushrooms have been used in therapeutic settings to help deal with various psychiatric disorders such as anxiety or addiction; the state of Oregon as gone so far as to legalize its medicinal use. In addition to this, MDMA phase 3 trials are currently being conducted, with many predicting that there could be an FDA-approved MDMA prescription treatment by the year 2023. Researchers are studying MDMA and its efficacy in the…

ThursdayJan 28, 2021 2:30 pm

First Psychedelics ETF in the World to Be Launched This Week

Horizon ETFs will be launching the first psychedelics exchange-traded fund in the world this week. This comes after the company announced that it had filed its final prospectus to introduce PSYK, its psychedelic stock index ETF. NEO Exchange has conditionally approved units of this stock for listing, with plans to start trading on Jan. 27, 2021. The stocks will be traded under the ticker PSYK. This will give investors a chance to buy stocks in a company that is focused on developing therapeutic solutions through the use of psychedelics. Extensive clinical research has shown that various psychedelic compounds have the…

ThursdayJan 28, 2021 11:45 am

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Increases Private Placement, Begins Trading on OTC Market

Pure Extracts upsizes private placement to total 16,900,000 special warrants at price of $0.505. PULL also received approval from OTC Markets, is trading on OTC Market under ticker symbol PRXTF. Trading under new OTC ticker is “major step forward,” says Company CEO. Pure Extracts Technologies (CSE PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, has increased its non-brokered private placement offering of special warrants; the original offering was announced on Dec. 16, 2020. The company also received approval from OTC Markets and is now trading on the OTC Market under the ticker symbol PRXTF. The Company observed that the…

WednesdayJan 27, 2021 3:00 pm

Advocates Worried by Insufficiency of Information on Psychedelic Treatments in Nova Scotia

Justin Andrews, co-founder of Halifax Psychedelic Society, a not-for-profit organization providing a safe space to connect and talk about psychedelics, is concerned that information on harm minimization strategies with regard to psychedelics is not being treated as a priority in Nova Scotia. Andrews assisted in the establishment of the organization in 2018. The objective of the organization was to offer harm-reduction information and a support system to individuals who would be interested in using psychedelic substances such as LSD and psilocybin as a therapeutic treatment. In this respect, harm-minimization strategies would comprise information about how to consume the psychedelic substances…

TuesdayJan 26, 2021 3:00 pm

Mount Sinai Opens Psychedelics Research Center

A new facility for psychedelics research, the Center for Psychedelic Psychotherapy and Trauma Research, was recently opened in New York City. The center follows a multifaceted research and clinical approach to finding new and more effective treatments for anxiety, depression, PTSD and other conditions linked to stress in both the civilian and veteran populations. The facility’s research will center on the study of psilocybin, MDMA and other psychedelic substances. MDMA, which is commonly known as ecstasy, is a psychoactive drug that may be used as a PTSD therapy treatment. Earlier in 2017, the U.S. FDA granted Breakthrough Therapy Designation status…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized